Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen

Experimental Hematology

Volumn 40, Issue 5, 2012, Pages 359-366

  Reddy, Nishitha ^a   Greer, John P ^a   Goodman, Stacey ^a   Kassim, Adetola ^a   Morgan, David S ^a   Chinratanalab, Wichai ^a   Brandt, Stephen ^a   Englehardt, Brian ^a   Oluwole, Olalekan ^a   Jagasia, Madan H ^a   Savani, Bipin N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LOADING DRUG DOSE; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PYRAZINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84859707074     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.01.012     Document Type: Article

References (38)

1. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
2. Navarro A., Royo C., Hernandez L., et al. Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications. Semin Hematol 2011, 48:155-165.
3. Czuczman M.S., Leonard J.P., Williams M.E. Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clin Adv Hematol Oncol 2010, 8:1-14. quiz 12p following page 14.
4. Chang J.E., Peterson C., Choi S., et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011, 155:190-197.
5. Kenkre V.P., Long W.L., Eickhoff J.C., et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011, 52:1675-1680.
6. Nabhan C., Ragam A., Bitran J.D., Mehta J. Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?. Bone Marrow Transplant 2010, 45:1379-1387.
7. Dreger P., Martin S., Kuse R., et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000, 1:87-94.
8. Jantunen E., Canals C., Attal M., et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012, 23:166-171.
9. Ritchie D.S., Seymour J.F., Grigg A.P., et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007, 86:101-105.
10. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793-800.
11. Tam C.S., Khouri I.F. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. Leuk Lymphoma 2009, 50:1239-1248.
12. Le Gouill S., Mohty M., Guillaume T., et al. Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?. Semin Hematol 2011, 48:227-239.
13. Shea T., Johnson J., Westervelt P., et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011, 17:1395-1403.
14. Cook G., Smith G.M., Kirkland K., et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010, 16:1419-1427.
15. Weniger M.A., Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol 2011, 48:214-226.
16. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
17. Smith S.D., Hsi E., Bolwell B., et al. Validation of the Mantle Cell Lymphoma International Prognostic Index: a single-center retrospective analysis. Am J Hematol 2010, 85:454-456.
18. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
19. Kimura Y., Sato K., Imamura Y., et al. Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. Cancer Sci 2011, 102:1734-1741.
20. Furtado M., Rule S. Indolent mantle cell lymphoma. Haematologica 2011, 96:1086-1088.
21. Romaguera J.E., Fayad L.E., Feng L., et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010, 150:200-208.
22. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
23. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
24. Mangel J., Leitch H.A., Connors J.M., et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004, 15:283-290.
25. van 't Veer M.B., de Jong D., MacKenzie M., et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009, 144:524-530.
26. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
27. Damon L.E., Johnson J.L., Niedzwiecki D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009, 27:6101-6108.
28. Hoster E. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin Hematol 2011, 48:185-188.
29. Geisler C.H., Kolstad A., Laurell A., et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010, 115:1530-1533.
30. Schaffel R., Hedvat C.V., Teruya-Feldstein J., et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010, 21:133-139.
31. Budde L.E., Guthrie K.A., Till B.G., et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011, 29:3023-3029.
32. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
33. Hartmann E.M., Campo E., Wright G., et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010, 116:953-961.
34. Pott C., Hoster E., Delfau-Larue M.H., et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010, 115:3215-3223.
35. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
36. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
37. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
38. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.